Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 134

1.

Natural heterogeneity of α2-antiplasmin: functional and clinical consequences.

Abdul S, Leebeek FW, Rijken DC, Uitte de Willige S.

Blood. 2016 Feb 4;127(5):538-45. doi: 10.1182/blood-2015-09-670117. Epub 2015 Dec 1. Review.

PMID:
26626994
2.

The Fibrinolytic Status in Liver Diseases.

Leebeek FW, Rijken DC.

Semin Thromb Hemost. 2015 Jul;41(5):474-80. doi: 10.1055/s-0035-1550437. Epub 2015 Jun 6. Review.

PMID:
26049070
3.

Plasma levels of soluble fibroblast activation protein in arterial thrombosis: determinants and cleavage of its substrate alpha-2-antiplasmin.

Uitte de Willige S, Malfliet JJ, Deckers JW, Dippel DW, Leebeek FW, Rijken DC.

Int J Cardiol. 2015 Jan 15;178:105-10. doi: 10.1016/j.ijcard.2014.10.091. Epub 2014 Oct 22.

PMID:
25464232
4.

Comment on Ågren et al. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes. Diabetes care 2014;37:2007-2014.

Rijken DC, Uitte de Willige S.

Diabetes Care. 2014 Nov;37(11):e243. doi: 10.2337/dc14-1336. No abstract available.

PMID:
25342840
5.

In black South Africans from rural and urban communities, the 4G/5G PAI-1 polymorphism influences PAI-1 activity, but not plasma clot lysis time.

de Lange Z, Rijken DC, Hoekstra T, Conradie KR, Jerling JC, Pieters M.

PLoS One. 2013 Dec 30;8(12):e83151. doi: 10.1371/journal.pone.0083151. eCollection 2013.

6.

Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis.

Uitte de Willige S, Malfliet JJ, Janssen HL, Leebeek FW, Rijken DC.

J Thromb Haemost. 2013 Nov;11(11):2029-36. doi: 10.1111/jth.12396.

7.

Identification and characterization of α1 -antitrypsin in fibrin clots.

Talens S, Malfliet JJ, van Hal PT, Leebeek FW, Rijken DC.

J Thromb Haemost. 2013 Jul;11(7):1319-28. doi: 10.1111/jth.12288.

8.

Fibrinogen γ' and variation in fibrinogen gamma genes in the etiology of portal vein thrombosis.

Smalberg JH, Koehler E, Darwish Murad S, Plessier A, Seijo S, Trebicka J, Primignani M, Rijken DC, de Maat MP, García-Pagán JC, Valla DC, Janssen HL, Leebeek FW; European Network for Vascular Disorders of the Liver (EN-Vie).

Thromb Haemost. 2013 Mar;109(3):558-60. doi: 10.1160/TH12-08-0632. Epub 2013 Jan 10. No abstract available.

PMID:
23306717
9.

Oxidized high-density lipoprotein reduces blood clot firmness.

Talens S, Malfliet JJ, Leebeek FW, Rijken DC.

J Thromb Haemost. 2013 Mar;11(3):561-3. doi: 10.1111/jth.12125. No abstract available.

10.

Plasma clot lysis time and its association with cardiovascular risk factors in black Africans.

de Lange Z, Pieters M, Jerling JC, Kruger A, Rijken DC.

PLoS One. 2012;7(11):e48881. doi: 10.1371/journal.pone.0048881. Epub 2012 Nov 8.

11.

Binding of carboxypeptidase N to fibrinogen and fibrin.

Talens S, Lebbink JH, Malfliet JJ, Demmers JA, Uitte de Willige S, Leebeek FW, Rijken DC.

Biochem Biophys Res Commun. 2012 Oct 19;427(2):421-5. doi: 10.1016/j.bbrc.2012.09.081. Epub 2012 Sep 21.

PMID:
23000409
12.

Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests.

Rijken DC, Kock EL, Guimarães AH, Talens S, Darwish Murad S, Janssen HL, Leebeek FW.

J Thromb Haemost. 2012 Oct;10(10):2116-22. doi: 10.1111/j.1538-7836.2012.04901.x.

13.

Identification of fibrin clot-bound plasma proteins.

Talens S, Leebeek FW, Demmers JA, Rijken DC.

PLoS One. 2012;7(8):e41966. doi: 10.1371/journal.pone.0041966. Epub 2012 Aug 3.

14.

Biological variation in tPA-induced plasma clot lysis time.

Talens S, Malfliet JJ, Rudež G, Spronk HM, Janssen NA, Meijer P, Kluft C, de Maat MP, Rijken DC.

Thromb Haemost. 2012 Oct;108(4):640-6. Epub 2012 Jul 26.

PMID:
22836204
15.

The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.

van der Pas R, de Bruin C, Leebeek FW, de Maat MP, Rijken DC, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, de Jong FH, van der Lely AJ, de Herder WW, Lamberts SW, Hofland LJ, Feelders RA.

J Clin Endocrinol Metab. 2012 Apr;97(4):1303-10. doi: 10.1210/jc.2011-2753. Epub 2012 Jan 25.

PMID:
22278425
16.

Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease.

De Wee EM, Klaij K, Eikenboom HC, Van Der Bom JG, Fijnvandraat K, Laros-Van Gorkom BA, Mauser-Bunschoten EP, Meijer K, Goverde G, Van Der Linden PW, Rijken DC, Leebeek FW; WiN Study Group.

Haemophilia. 2012 May;18(3):444-51. doi: 10.1111/j.1365-2516.2011.02645.x. Epub 2011 Sep 12.

PMID:
21910790
17.

Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences.

Smalberg JH, Kruip MJ, Janssen HL, Rijken DC, Leebeek FW, de Maat MP.

Arterioscler Thromb Vasc Biol. 2011 Mar;31(3):485-93. doi: 10.1161/ATVBAHA.110.213371. Review.

18.

High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease.

de Bruijne EL, Gils A, Rijken DC, de Maat MP, Guimarães AH, Poldermans D, Declerck PJ, Leebeek FW.

Thromb Res. 2011 Mar;127(3):254-8. doi: 10.1016/j.thromres.2010.11.026. Epub 2010 Dec 30.

19.

Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd-Chiari syndrome.

Talens S, Hoekstra J, Dirkx SP, Darwish Murad S, Trebicka J, Elias E, Primignani M, García-Pagán JC, Valla DC, Janssen HL, Leebeek FW, Rijken DC; EN-Vie Study Group.

J Hepatol. 2011 May;54(5):908-14. doi: 10.1016/j.jhep.2010.08.026. Epub 2011 Jan 14.

PMID:
21145806
20.

The effect of ethanol and its metabolism on fibrinolysis.

Pieters M, Vorster HH, Jerling JC, Venter CS, Kotze RC, Bornman E, Malfliet JJ, Rijken DC.

Thromb Haemost. 2010 Oct;104(4):724-33. doi: 10.1160/TH10-01-0048. Epub 2010 Jul 20.

PMID:
20664891
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk